W

Wellington Management

Global asset management for institutional clients

Video Production Manager

Full-TimeUpdated on 10/22/2026
$120k - $225k+ Discretionary corporate bonus + Incentives
Expert
Bachelor's
Boston, MA, USA
HybridEmployees work in the office 4 days a week and may work remotely 1 day a week; travel is required for on-site shoots.
Creative ProductionVideo Production & Editing
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A hands-on self-shooter must be able to own both camera and editing, with character-driven, documentary-style work that finds the human story inside a business context.
  • Strong technical skills in DSLR/cinema camera videography, lighting design, and audio recording, including high-end interview and brand shoots.
  • Expertise in non-linear editing and post-production, including color grading using DaVinci Resolve or Premiere color tools, and sound design/mixing beyond basic audio cleanup.
  • A portfolio or reel demonstrating a premium editorial eye and polish appropriate for a global investment firm's brand.
  • Executive presence and clear, confident communication to direct C-suite executives and senior portfolio managers on set, provide tactful real-time feedback, and earn trust quickly.
  • Comfort working with senior executives and client-facing subject matter in a regulated industry.
  • Strong organizational skills and the ability to manage multiple projects in a fast-paced environment.
  • Ability to travel for on-site shoots and handle physical production tasks.
  • Bachelor's degree in Film, Communications, Marketing, or a related field.
  • Minimum 10+ years of video production experience, ideally including in-house work at a financial services, professional services, or corporate brand.
Responsibilities
  • Develop concepts and scripts; film with professional camera equipment; and edit, finish, and deliver content in Adobe Creative Suite, including Premiere Pro, After Effects, Photoshop, and Audition, with motion graphics and audio post-production.
  • Partner with brand and marketing leadership to shape each project's idea, narrative, and treatment, then own the camera, edit, and cinematic standard as a hands-on self-shooter.
  • Act as a trusted creative advisor to senior investors and executives, providing media training, real-time coaching, and narrative direction to achieve a polished, professional result.
  • Maintain visual judgment across cinematography, lighting, composition, pacing, color grading, and sound design to deliver high-quality work that reflects Wellington's global brand.
  • Partner with brand and marketing leadership on video strategy and the content calendar; own the video budget and vendor selection; and manage junior producers, freelancers, and outside agency crews.
  • Lead signoffs, compliance review, releases, and approvals in coordination with Legal and Compliance, navigating reputational sensitivity independently.
  • Work with marketing, brand, and investment teams to translate technical subject matter into clear visual stories, using AI-assisted production tools to increase output without sacrificing quality.
  • Maintain the video asset library, production calendars, and viewership metrics, while staying current on platform best practices, emerging production tools, and new techniques.
Desired Qualifications
  • Experience with podcast production, motion graphics for data visualization, and drone operation, including FAA Part 107 certification, is a plus.

About the company

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$65.9B

Headquarters

Boston, Massachusetts

Founded

1933

Get referred to Wellington Management

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Hartford Funds acquisition closes in first quarter 2027, adding wealth distribution.
  • The new Wellington-Vanguard-Blackstone solutions expand access to public-private portfolios.
  • Wellington’s venture, biotech, climate, and CLO launches broaden fee-bearing alternatives.

What critics are saying

  • Hartford Funds integration carries execution risk until regulators approve the Q1 2027 close.
  • Steve Klar’s retirement in June 2026 exposes client-platform succession risk.
  • Passive giants and private-credit rivals compress Wellington’s fees and threaten AUM growth.

What makes Wellington Management unique

  • Wellington blends public and private markets through alliances with Vanguard and Blackstone.
  • Its $1.35 trillion platform spans 60 countries and over 2,500 institutional clients.
  • Matt Witheiler’s Forbes Midas List streak validates Wellington’s late-stage growth investing credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Comprehensive health coverage
  • Work-life balance
  • Financial future
  • Development

Company News

The Information
Oct 15th, 2026
Mueon raises $65M to pack up to 10x more AI computing into data centres

Portland-based startup Mueon has raised $65 million to develop a new way to arrange AI server rack components. The company says its design could fit up to 10 times more computing capacity into the same amount of power as existing data centre setups. The approach could ease constraints on global computing capacity.

Business Wire
Oct 13th, 2026
Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program

Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing orally bioavailable, small molecule therapies for musculoskeletal diseases, toda...

MarketScreener
Oct 13th, 2026
Alaunos Therapeutics to raise $350M in private placement led by Fairmount

Alaunos Therapeutics has agreed to raise about $349.95 million through a private placement of stock. It signed a Securities Purchase Agreement to sell 687,789 shares of common stock at $1.4357 per share and 243,063 shares of Series C preferred stock at $1,435.70 per share. The common stock brings in about $987,459, and the preferred stock about $348.97 million. The deal is expected to close on October 14, 2026, subject to customary closing conditions. Fairmount led the placement of Series C non-voting convertible preferred stock. Venrock Healthcare Capital Partners, T. Rowe Price Investment Management, Wellington Management, Janus Henderson Investors, Access Biotechnology, BB Biotech, Perceptive Advisors, Sirenia Capital Management, ADAR1 Capital Management and other firms took part.

LinkedIn
Sep 30th, 2026
We just closed an employee tender offer which values ElevenLabs at $22BN, up 2x from our Series D in February. The tender was led by Wellington and T. Rowe Price, and the growth is driven by demand… | Mati Staniszewski | 89 comments

We just closed an employee tender offer which values ElevenLabs at $22BN, up 2x from our Series D in February. The tender was led by Wellington and T. Rowe Price, and the growth is driven by demand from enterprises to deploy ElevenAgents across sales, support, and operations. In 2022, we raised our first round at a $9 million valuation, which we announced alongside Eleven v1, our first Text to Speech model, and the first model to generate human-level speech. Four years later, as we reach our new valuation, we just released two new state-of-the-art Text to Speech models. Eleven v4 and v4 Turbo are our fastest and most emotive models yet, and are leading independent benchmarks. Alongside models, we have built a full interaction platform for AI. It allows organizations to deploy conversational agents, connected to their knowledge and systems, that interact naturally in any industry, geography, or context. This shift is driving much of our growth, with enterprise now accounting for 55% of our revenue, as businesses adopt ElevenAgents to support their customers and employees. Our technology is now used in daily operations at five of the world’s ten largest tech companies, five of the ten largest insurers, and four of the ten largest telecoms. The round was co-led by Wellington Management and T. Rowe Price, along with participation from Goldman Sachs, GIC, Ontario Teachers'​ Pension Plan, EQT Group, Sapphire Ventures, and BDT & MSD Partners. And grateful for ongoing support from existing investors including Andreessen Horowitz, Alkeon Capital, The D. E. Shaw Group, Disruptive, Evantic Capital, ICONIQ, and Lightspeed. Most of all, this round is for the team that built the last four years. We're just getting started! | 89 comments on LinkedIn

MarketScreener
Sep 29th, 2026
Immix Biopharma prices $125M stock offering to fund AL amyloidosis therapy development

Immix Biopharma has priced an underwritten public offering of 11,363,637 shares of common stock at $11.00 per share, expecting gross proceeds of $125 million before deducting underwriting discounts and expenses. The offering is expected to close on or about 30 September 2026. The company intends to use the net proceeds to fund development of NXC-201, working capital, and general corporate purposes. NXC-201 is a CAR-T cell therapy being evaluated for relapsed/refractory AL Amyloidosis and has received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy designation from the US FDA. J.P. Morgan is acting as sole book-running manager. The offering included participation from institutional investors including Eventide Asset Management, Janus Henderson Investors, Ridgeback Capital Investments, and Wellington Management.